Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07077213 · ClinicalTrials.gov registry record
18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
A clinical trial, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- 30
- Enrollment target
NCT07077213 is a clinical trial that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 30 participants.
The verdict
NCT07077213 is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung disease and fibrosis in TB patients. Microbiologically confirmed patients with active tuberculosis will be invited to participate in the study. A whole-body PET scan will be performed after 18F-FAPI-74 intravenous injection and correlation will be made with sites of TB lesions noted on CT. It is anticipated that 18F-FAPI-74 PET will be able to detect fibrosis (with high sensitivity) in the TB lesions.
Interventions
- COMBINATION_PRODUCT 18F-FAPI-74
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-12 |
| Est. Completion | 2027-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07077213
The ClinicalTrials.gov registry entry for NCT07077213 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-FAPI-74 is the first listed.
NCT07077213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07077213 about?
NCT07077213 is a clinical study titled "18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients". The investigators will assess the hypothesis is that 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) Positron emission tomography (PET) could be used as a noninvasive biomarker to assess post-tuberculosis (post-TB) lung disease and fibrosis in TB patients. Microbiologically confirmed pati...
What is the current status of trial NCT07077213?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-03-12. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07077213?
The interventions under investigation include: 18F-FAPI-74 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07077213?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.